In patients with heart failure with improved ejection fraction (EF), pharmacological therapy is rarely withdrawn, according ...

BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended ...

Among successful revascularizations, there was a hint of better outcomes compared with OMT, but the data need confirmation.

New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca's TAGRISSO® (osimertinib), as monotherapy and as the backbone for ...

People who have early signs of heart problems may also have changes in brain health that can be early signs of dementia, such ...

First-ever positive profit, entering a new era of growth and global innovation ...

First-ever positive profit, entering a new era of growth and global innovation SAN FRANSISCO and SUZHOU, China, March 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: ...

In patients with metabolic dysfunction-associated steatotic liver disease, there is increased risk for heart failure with preserved ejection fraction.